Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.

Bibliographic Details
Main Authors: Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura, Yusuke Sakai, Yumi Itoh, Fuminori Sugihara, Yoshiharu Matsuura, Satoaki Matoba, Toru Okamoto, Junichi Takagi, Atsushi Hoshino
Format: Article
Language:English
Published: Nature Portfolio 2021-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-24013-y

Internet

https://doi.org/10.1038/s41467-021-24013-y

Similar Items